Plasmid-encoded tet(X) genes that confer high-level tigecycline resistance in Escherichia coli

Research output: Contribution to journalLetter

13 Citations (Scopus)

Abstract

Tigecycline is one of the last-resort antibiotics to treat complicated infections caused by both multidrug-resistant Gram-negative and Gram-positive bacteria1. Tigecycline resistance has sporadically occurred in recent years, primarily due to chromosome-encoding mechanisms, such as overexpression of efflux pumps and ribosome protection2,3. Here, we report the emergence of the plasmid-mediated mobile tigecycline resistance mechanism Tet(X4) in Escherichia coli isolates from China, which is capable of degrading all tetracyclines, including tigecycline and the US FDA newly approved eravacycline. The tet(X4)-harbouring IncQ1 plasmid is highly transferable, and can be successfully mobilized and stabilized in recipient clinical and laboratory strains of Enterobacteriaceae bacteria. It is noteworthy that tet(X4)-positive E. coli strains, including isolates co-harbouring mcr-1, have been widely detected in pigs, chickens, soil and dust samples in China. In vivo murine models demonstrated that the presence of Tet(X4) led to tigecycline treatment failure. Consequently, the emergence of plasmid-mediated Tet(X4) challenges the clinical efficacy of the entire family of tetracycline antibiotics. Importantly, our study raises concern that the plasmid-mediated tigecycline resistance may further spread into various ecological niches and into clinical high-risk pathogens. Collective efforts are in urgent need to preserve the potency of these essential antibiotics.

Original languageEnglish (US)
Pages (from-to)1457-1464
Number of pages8
JournalNature Microbiology
Volume4
Issue number9
DOIs
StatePublished - Sep 1 2019

Fingerprint

Plasmids
Escherichia coli
Genes
Anti-Bacterial Agents
China
Tetracyclines
Enterobacteriaceae
Tetracycline
Treatment Failure
Dust
Ribosomes
tigecycline
Chickens
Swine
Soil
Chromosomes
Bacteria
Infection

All Science Journal Classification (ASJC) codes

  • Applied Microbiology and Biotechnology
  • Microbiology (medical)
  • Genetics
  • Cell Biology
  • Microbiology
  • Immunology

Cite this

@article{4cf85eabc7b944b8b8ed641f5f71a835,
title = "Plasmid-encoded tet(X) genes that confer high-level tigecycline resistance in Escherichia coli",
abstract = "Tigecycline is one of the last-resort antibiotics to treat complicated infections caused by both multidrug-resistant Gram-negative and Gram-positive bacteria1. Tigecycline resistance has sporadically occurred in recent years, primarily due to chromosome-encoding mechanisms, such as overexpression of efflux pumps and ribosome protection2,3. Here, we report the emergence of the plasmid-mediated mobile tigecycline resistance mechanism Tet(X4) in Escherichia coli isolates from China, which is capable of degrading all tetracyclines, including tigecycline and the US FDA newly approved eravacycline. The tet(X4)-harbouring IncQ1 plasmid is highly transferable, and can be successfully mobilized and stabilized in recipient clinical and laboratory strains of Enterobacteriaceae bacteria. It is noteworthy that tet(X4)-positive E. coli strains, including isolates co-harbouring mcr-1, have been widely detected in pigs, chickens, soil and dust samples in China. In vivo murine models demonstrated that the presence of Tet(X4) led to tigecycline treatment failure. Consequently, the emergence of plasmid-mediated Tet(X4) challenges the clinical efficacy of the entire family of tetracycline antibiotics. Importantly, our study raises concern that the plasmid-mediated tigecycline resistance may further spread into various ecological niches and into clinical high-risk pathogens. Collective efforts are in urgent need to preserve the potency of these essential antibiotics.",
author = "Kreiswirth, {Barry N.} and Liang Chen",
year = "2019",
month = "9",
day = "1",
doi = "https://doi.org/10.1038/s41564-019-0496-4",
language = "English (US)",
volume = "4",
pages = "1457--1464",
journal = "Nature Microbiology",
issn = "2058-5276",
publisher = "Nature Publishing Group",
number = "9",

}

Plasmid-encoded tet(X) genes that confer high-level tigecycline resistance in Escherichia coli. / Kreiswirth, Barry N.; Chen, Liang.

In: Nature Microbiology, Vol. 4, No. 9, 01.09.2019, p. 1457-1464.

Research output: Contribution to journalLetter

TY - JOUR

T1 - Plasmid-encoded tet(X) genes that confer high-level tigecycline resistance in Escherichia coli

AU - Kreiswirth, Barry N.

AU - Chen, Liang

PY - 2019/9/1

Y1 - 2019/9/1

N2 - Tigecycline is one of the last-resort antibiotics to treat complicated infections caused by both multidrug-resistant Gram-negative and Gram-positive bacteria1. Tigecycline resistance has sporadically occurred in recent years, primarily due to chromosome-encoding mechanisms, such as overexpression of efflux pumps and ribosome protection2,3. Here, we report the emergence of the plasmid-mediated mobile tigecycline resistance mechanism Tet(X4) in Escherichia coli isolates from China, which is capable of degrading all tetracyclines, including tigecycline and the US FDA newly approved eravacycline. The tet(X4)-harbouring IncQ1 plasmid is highly transferable, and can be successfully mobilized and stabilized in recipient clinical and laboratory strains of Enterobacteriaceae bacteria. It is noteworthy that tet(X4)-positive E. coli strains, including isolates co-harbouring mcr-1, have been widely detected in pigs, chickens, soil and dust samples in China. In vivo murine models demonstrated that the presence of Tet(X4) led to tigecycline treatment failure. Consequently, the emergence of plasmid-mediated Tet(X4) challenges the clinical efficacy of the entire family of tetracycline antibiotics. Importantly, our study raises concern that the plasmid-mediated tigecycline resistance may further spread into various ecological niches and into clinical high-risk pathogens. Collective efforts are in urgent need to preserve the potency of these essential antibiotics.

AB - Tigecycline is one of the last-resort antibiotics to treat complicated infections caused by both multidrug-resistant Gram-negative and Gram-positive bacteria1. Tigecycline resistance has sporadically occurred in recent years, primarily due to chromosome-encoding mechanisms, such as overexpression of efflux pumps and ribosome protection2,3. Here, we report the emergence of the plasmid-mediated mobile tigecycline resistance mechanism Tet(X4) in Escherichia coli isolates from China, which is capable of degrading all tetracyclines, including tigecycline and the US FDA newly approved eravacycline. The tet(X4)-harbouring IncQ1 plasmid is highly transferable, and can be successfully mobilized and stabilized in recipient clinical and laboratory strains of Enterobacteriaceae bacteria. It is noteworthy that tet(X4)-positive E. coli strains, including isolates co-harbouring mcr-1, have been widely detected in pigs, chickens, soil and dust samples in China. In vivo murine models demonstrated that the presence of Tet(X4) led to tigecycline treatment failure. Consequently, the emergence of plasmid-mediated Tet(X4) challenges the clinical efficacy of the entire family of tetracycline antibiotics. Importantly, our study raises concern that the plasmid-mediated tigecycline resistance may further spread into various ecological niches and into clinical high-risk pathogens. Collective efforts are in urgent need to preserve the potency of these essential antibiotics.

UR - http://www.scopus.com/inward/record.url?scp=85068157605&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068157605&partnerID=8YFLogxK

U2 - https://doi.org/10.1038/s41564-019-0496-4

DO - https://doi.org/10.1038/s41564-019-0496-4

M3 - Letter

C2 - 31235960

VL - 4

SP - 1457

EP - 1464

JO - Nature Microbiology

JF - Nature Microbiology

SN - 2058-5276

IS - 9

ER -